Antibiotic development — economic, regulatory and societal challenges

被引：0

作者：

Christine Årdal

Manica Balasegaram

Ramanan Laxminarayan

David McAdams

Kevin Outterson

John H. Rex

Nithima Sumpradit

机构：

[1] Norwegian Institute of Public Health,Fuqua School of Business and Economics Department

[2] Global Antibiotic R&D Partnership,undefined

[3] Center for Disease Dynamics,undefined

[4] Economics & Policy,undefined

[5] Duke University,undefined

[6] Boston University,undefined

[7] F2G Ltd,undefined

[8] Food and Drug Administration,undefined

[9] Ministry of Public Health,undefined

来源：

Nature Reviews Microbiology | 2020年 / 18卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

Antibiotic resistance is undoubtedly one of the greatest challenges to global health, and the emergence of resistance has outpaced the development of new antibiotics. However, investments by the pharmaceutical industry and biotechnology companies for research into and development of new antibiotics are diminishing. The public health implications of a drying antibiotic pipeline are recognized by policymakers, regulators and many companies. In this Viewpoint article, seven experts discuss the challenges that are contributing to the decline in antibiotic drug discovery and development, and the national and international initiatives aimed at incentivizing research and the development of new antibiotics to improve the economic feasibility of antibiotic development.

引用

页码：267 / 274

页数：7

共 21 条

[1]

Payne DJ(2007)Drugs for bad bugs: confronting the challenges of antibacterial discovery Nat. Rev. Drug Discov. 6 29-187

[2]

Gwynn MN(2018)Insights into early stage of antibiotic development in small-and medium-sized enterprises: a survey of targets, costs, and durations J. Pharm. Policy Pract. 11 176-72

[3]

Holmes DJ(2016)Understanding the mechanisms and drivers of antimicrobial resistance Lancet 387 411-75

[4]

Pompliano DL(2019)Achaogen bankruptcy highlights antibacterial development woes Nat. Rev. Drug Discov. 18 396-undefined

[5]

Årdal C(2019)Resistance diagnostics as a public health tool to combat antibiotic resistance: A model-based evaluation PLOS Biol. 17 1082-undefined

[6]

Holmes AH(2018)Vital signs: containment of novel multidrug-resistant organisms and resistance mechanisms—United States, 2006–2017 Morb. Mortal. Wkly Rep. 67 61-undefined

[7]

Mullard A(2004)Limited spread of penicillin-nonsusceptible pneumococci, Skåne County , Sweden Emerg. Infect. Dis. 10 67-undefined

[8]

McAdams D(2019)Non-traditional antibacterial therapeutic options and challenges Cell Host Microb. 26 undefined-undefined

[9]

Waldetoft KW(2018)Consumption of oral antibiotic formulations for young children according to the WHO Access, Watch, Reserve (AWaRe) antibiotic groups: an analysis of sales data from 70 middle-income and high-income countries Lancet Infect. Dis. 19 undefined-undefined

[10]

Tedijanto C(undefined)undefined undefined undefined undefined-undefined

← 1 2 3 →